Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
Executive Summary
Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.
You may also be interested in...
Mustang Bio’s MB-101 Gallops To Win In Glioblastoma
The lead author on the Phase I study told Scrip that in addition to targeting a widely expressed antigen on GBM tumors, the CAR-T also stimulates the body’s immune system.
Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
Finance Watch: Nkarta, Passage Bio Raise Venture Capital Mega-Rounds
Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.